Revolutionary transparent graphene microelectrodes enhance brain imaging and stimulation

The decoding of single-cell and average neural activities from surface potentials.

After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penalty

The rise and fall of the short-lived biotech Zymergen has ended with a $30 million penalty from the SEC. Zymergen’s rise began in April 2021

September 14, 2024

Rapport bags $150M Series B just five months after nine-figure launch for epilepsy, psychiatry trials

Just five months after emerging with $100 million to test former Janssen neuroscience programs, Rapport Therapeutics is back with another nine-figure raise to take its

August 24, 2023

Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition

October 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.